Search Results - "Giannarelli, D."

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab by Ferrucci, P.F., Ascierto, P.A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G.C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., Simeone, E., Valpione, S., Altomonte, M., Spagnolo, F., Cocorocchio, E., Gandini, S., Giannarelli, D., Martinoli, C.

“…Clinical responses to ipilimumab are variable in terms of onset, magnitude and duration. Upfront identification of patients who are more likely or unlikely to…”
Get full text

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients by Ferrucci, P F, Gandini, S, Battaglia, A, Alfieri, S, Di Giacomo, A M, Giannarelli, D, Cappellini, G C Antonini, De Galitiis, F, Marchetti, P, Amato, G, Lazzeri, A, Pala, L, Cocorocchio, E, Martinoli, C

“…Background: Ipilimumab improves the survival of metastatic melanoma patients. Despite documented, durable objective responses, a significant number of patients…”
Get full text

Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study by Nelli, F., Fabbri, A., Onorato, A., Giannarelli, D., Silvestri, M.A., Giron Berrios, J.R., Virtuoso, A., Marrucci, E., Signorelli, C., Chilelli, M.G., Primi, F., Schirripa, M., Mazzotta, M., Ruggeri, E.M.

Get full text

Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer by Di Noia, V., Pimpinelli, F., Renna, D., Barberi, V., Pellini, R., Morrone, A., Giannarelli, D., Cognetti, F.

Get full text

Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial by PACE, A, GIANNARELLI, D, JANDOLO, B, BOVE, L, COGNETTI, F, GALIE, E, SAVARESE, A, CARPANO, S, DELLA GIULIA, M, POZZI, A, SILVANI, A, GAVIANI, P, SCAIOLI, V

“…The clinical use of cisplatin chemotherapy is limited by severe peripheral neurotoxicity reported in up to 90% of patients receiving a cumulative dose higher…”
Get full text

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab by Ferrucci, P.F., Ascierto, P.A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G.C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., Simeone, E., Valpione, S., Altomonte, M., Spagnolo, F., Cocorocchio, E., Gandini, S., Giannarelli, D., Martinoli, C.

Get full text

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis by Bria, E., Milella, M., Cuppone, F., Novello, S., Ceribelli, A., Vaccaro, V., Sperduti, I., Gelibter, A., Scagliotti, G.V., Cognetti, F., Giannarelli, D.

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are effective as first-line treatment of advanced non-small-cell lung cancer patients…”
Get full text

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study by Di Giacomo, A.M., Ascierto, P.A., Queirolo, P., Pilla, L., Ridolfi, R., Santinami, M., Testori, A., Simeone, E., Guidoboni, M., Maurichi, A., Orgiano, L., Spadola, G., Del Vecchio, M., Danielli, R., Calabrò, L., Annesi, D., Giannarelli, D., Maccalli, C., Fonsatti, E., Parmiani, G., Maio, M.

“…Long-term analysis of the NIBIT-M1 trial continues to demonstrate efficacy of the combination of ipilimumab and fotemustine in metastatic melanoma patients…”
Get full text

Effectiveness of continuous wound infusion of 0.5% ropivacaine by On-Q pain relief system for postoperative pain management after open nephrectomy by Forastiere, E., Sofra, M., Giannarelli, D., Fabrizi, L., Simone, G.

“…Block of parietal nociceptive afferent nerves using continuous wound infiltration with local anaesthetics may be beneficial in multimodal postoperative pain…”
Get full text

Radiomics analysis of ultrasound images to discriminate between benign and malignant adnexal masses with solid ultrasound morphology by Moro, F, Vagni, M, Tran, H E, Bernardini, F, Mascilini, F, Ciccarone, F, Nero, C, Giannarelli, D, Boldrini, L, Fagotti, A, Scambia, G, Valentin, L, Testa, A C

“…Our primary aim was to identify radiomic ultrasound features that can distinguish benign from malignant adnexal masses with solid ultrasound morphology, and…”
Get full text

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer by Di Noia, V., Pimpinelli, F., Renna, D., Maccallini, M.T., Gariazzo, L., Riva, F., Sperandio, E., Giannarelli, D., Cognetti, F.

Get full text

Subjective assessment and IOTA ADNEX model in evaluation of adnexal masses in patients with history of breast cancer by Pozzati, F., Sassu, C. M., Marini, G., Mascilini, F., Biscione, A., Giannarelli, D., Garganese, G., Fragomeni, S. M., Scambia, G., Testa, A. C., Moro, F.

“…ABSTRACT Objective To evaluate the performance of subjective assessment and the Assessment of Different NEoplasias in the adneXa (ADNEX) model in…”
Get full text

Propolis in the prevention of oral mucositis in breast cancer patients receiving adjuvant chemotherapy: A pilot randomised controlled trial by Piredda, M., Facchinetti, G., Biagioli, V., Giannarelli, D., Armento, G., Tonini, G., De Marinis, M.G.

“…Chemo‐induced oral mucositis (OM) is associated with significant symptoms, treatment delays and increased costs. This pilot randomised controlled trial aimed…”
Get full text

Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study by Nelli, F., Virtuoso, A., Berrios, J. R. Giron, Giannarelli, D., Fabbri, A., Marrucci, E., Ruggeri, E. M.

“…Background Immunosuppressive dosing of corticosteroids at the start of treatment impairs immune checkpoint inhibitor (ICI) efficacy in advanced non-small cell…”
Get full text

OP14.04: Ultrasound‐based radiomics analysis for discriminating between benign and malignant ovarian masses with solid ultrasound morphology by Moro, F., Bernardini, F., Tran, H., Vagni, M., Boldrini, L., Ciccarone, F., Nero, C., Mascilini, F., Pozzati, F., Quagliozzi, L., Giannarelli, D., Scambia, G., Valentin, L., Testa, A. C.

Get full text

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine by Metro, G., Foglietta, J., Russillo, M., Stocchi, L., Vidiri, A., Giannarelli, D., Crinò, L., Papaldo, P., Mottolese, M., Cognetti, F., Fabi, A., Gori, S.

“…In the present study, we investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive…”
Get full text

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial by Cognetti, F., Ruggeri, E.M., Felici, A., Gallucci, M., Muto, G., Pollera, C.F., Massidda, B., Rubagotti, A., Giannarelli, D., Boccardo, F., Cantiani, R., Aglietta, M., Bertetto, O., Cetto, G.L., Orlandini, P., Ferrazzi, E., Nardi, M., della Sofferenza, Sollievo, Manzione, L., Adamo, V., Porcile, G., Lentini, M., Breda, E., Gamucci, T., Tummarello, D., Dogliotti, L., Tumolo, S., Motta, M., Lo Russo, V., De Grande, G., Sacco, C., Gaion, F., Lavarello, A., Nuzzo, A., Clerico, M., Aragona, C., Gernone, A., Morelli, F., Olivito, V., Cupini, Mattioli, R., Marra, A., Antimi, M., Silingardi, V., Labianca, R., Martoni, A., Bortolussi, V., Luoni, M., Rosabian, A., Di Vito, F., Catalano, G., Gebbia, N.

“…The purpose of the study was to evaluate the benefit of adjuvant chemotherapy (AC) versus surgery alone in patients with muscle-invasive bladder cancer (MIBC)…”
Get full text

Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study by Nelli, F., Giannarelli, D., Fabbri, A., Silvestri, M.A., Berrios, J. R. Giron, Virtuoso, A., Marrucci, E., Schirripa, M., Mazzotta, M., Onorato, A., Panichi, V., Topini, G., Pessina, G., Natoni, F., Signorelli, C., Chilelli, M.G., Primi, F., Ruggeri, E.M.

Get full text

Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study by Marchesi, F, Tendas, A, Giannarelli, D, Viggiani, C, Gumenyuk, S, Renzi, D, Franceschini, L, Caffarella, G, Rizzo, M, Palombi, F, Pisani, F, Romano, A, Spadea, A, Papa, E, Canfora, M, Pignatelli, A, Cantonetti, M, Arcese, W, Mengarelli, A

Get full text

Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study by Nelli, F., Fabbri, A., Onorato, A., Giannarelli, D., Silvestri, M.A., Pessina, G., Giron Berrios, J.R., Virtuoso, A., Marrucci, E., Schirripa, M., Mazzotta, M., Panichi, V., Cercola, P., Signorelli, C., Chilelli, M.G., Primi, F., Ruggeri, E.M.

Get full text